Treatment Outcome Measures for Spasmodic Dysphonia: A Systematic Review

Rumbach, Anna F.; Aiken, Patrick; Novakovic, Daniel

doi:10.1016/j.jvoice.2021.10.001

Cited by 6 publications

(13 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The review concluded that there is currently no unified approach to the measurement of outcomes in LD treatment research. It is recommended that a core outcome set be developed and implemented to facilitate the assessment of current and new treatments for LD [129].…”

Section: Assessment Of Treatment Outcomesmentioning

confidence: 99%

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

Yeung

Richards

Novakovic

2022

Toxins

Self Cite

View full text Add to dashboard Cite

Laryngeal dystonia (LD), or spasmodic dysphonia (SD), is a chronic, task-specific, focal movement disorder affecting the larynx. It interferes primarily with the essential functions of phonation and speech. LD affects patients’ ability to communicate effectively and significantly diminishes their quality of life. Botulinum neurotoxin was first used as a therapeutic agent in the treatment of LD four decades ago and remains the standard of care for the treatment of LD. This article provides an overview of the clinical application of botulinum neurotoxin in the management of LD, focusing on the classification for this disorder, its pathophysiology, clinical assessment and diagnosis, the role of laryngeal electromyography and a summary of therapeutic injection techniques, including a comprehensive description of various procedural approaches, recommendations for injection sites and dosage considerations.

show abstract

Section: Assessment Of Treatment Outcomesmentioning

confidence: 99%

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

Yeung

Richards

Novakovic

2022

Toxins

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is a lack of universal consensus on the best outcome measurement instruments to evaluate disease severity and treatment success. [3][4][5][6][7][8][9] For both voice conditions, currently existing treatments are suboptimal in many regards. The current gold standard treatment, the use of laryngeal injection of Botulinum Toxin A (BoNT-A), [10][11][12] has several well-identified drawbacks.…”

Section: Introductionmentioning

confidence: 99%

“…The current gold standard treatment, the use of laryngeal injection of Botulinum Toxin A (BoNT-A), [10][11][12] has several well-identified drawbacks. Treatment requires repetitive dosing, there are potential side effects such as dysphagia and weak/breathy voice, 10 specialized technical skill is required to perform the injection, 4 failed injections (or socalled "misses") 13,14 can occur, and there is a subset of patients with minimal response or resistance to BoNT-A treatment. 15,16 As such, many have sought to innovate new techniques and therapeutics.…”

Section: Introductionmentioning

confidence: 99%

“…Unfortunately, these publications tend to be of small sample size, and the heterogeneity of reported outcome measures further limits the ability to draw conclusions across studies. 3,4 For instance, publication on the selective laryngeal adductor denervation-reinnervation procedure used Voice Handicap Index-10 (VHI-10) and perceptual evaluation for voice breaks and breathiness as outcome measures. 17 The only published randomized controlled trial exploring the use of sodium oxybate incorporated blinded randomized analyses counting a number of voice breaks and rating of voice for harshness, breathiness, and tremor severity on a VAS.…”

Section: Introductionmentioning

confidence: 99%

“…A majority of publications exploring treatment effects within the laryngeal dystonia population include at least some PROM as an outcome measure. 3,4 They can provide a patient-centered contextualization of symptom severity and the impact of the voice disorder on quality of life. Additionally, for the clinician, PROMs can provide a method of monitoring response to treatment over time.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exploring Patient's Preference of Patient‐Reported Outcome Measures in Laryngeal Movement Disorders

et al. 2022

View full text Add to dashboard Cite

Background: Despite many available patient-reported outcome measures (PROMs) for laryngeal movement disorders, there is a lack of patient input regarding which PROM most accurately and conveniently captures aspects related to their vocal disease. This study aimed to assess patients' preferences among a selection of voice-related PROMs (Voice Handicap Index-10 [VHI-10], OMNI-Vocal Effort Scale [OMNI-VES], Communicative Participation Item Bank-General Short Form [CPIB-10], and Visual Analog Scales [VAS]) within the laryngeal movement disorder population and investigate associations between selected instruments.Methods: Prior to botulinum toxin A injection, patients with laryngeal dystonia and/or essential tremor of the vocal tract were administered the VHI-10, OMNI-VES, CPIB-10, and three novel VAS questions in a randomized order. Patients rank ordered the four PROMs based on the PROMs' reflection of their voice problems. Pearson's correlation coefficients evaluated pairwise associations among PROM scores. Fisher's exact test compared the preferred PROM rankings.Results: Seventy patients (53 female, mean age = 60.7 years) participated. The VHI-10 and CPIB-10 were most preferred at 33.9% and 27.4% respectively. The OMNI-VES and VAS scales were less favored (19.4%, each). When analyzed by age ≥60 years, the CPIB-10 was most favored (33.3%), but for age <60 years, VHI-10 was most preferred (42.3%). There was a strong correlation between scores of all administered PROMs (strongest correlation between OMNI-VES and VAS, r = 0.8, p < 0.001; the weakest correlation between OMNI-VES and VHI-10, r = 0.6, p < 0.001).Conclusions: With an increasing trend in PROMs usage and a strong correlation between all evaluated outcome instruments, insight regarding patients' PROM preferences is an area for further consideration.

show abstract

Durability of Titanium Implants Following Type II Thyroplasty for Adductor Type Spasmodic Dysphonia

Toya¹,

Hiroshiba²

2023

The Laryngoscope

View full text Add to dashboard Cite

ObjectiveTo determine the durability of current titanium implants (TI) used in voice improvement surgery for adductor spasmodic dysphonia (ADSD), which is type II thyroplasty (T2T), and identify the effects of their fractures on vocal functions.MethodsA total of 36 ADSD patients who underwent T2T had the following exams: The CT scans of the larynx were performed 1 year after the surgery to assess the fractures of TI. The improvement in the mean voice handicap index 10 (VHI‐10) scores and the success rate between nonfractured (NFR) and fractured (FR) groups were compared.ResultsIt was indicated that TI was broken in 21 cases (58.3%). In one case (2.7%), a fracture on the part of the bridge that connects both sides of the plates was observed, and fractures at holes placed on the plates in the other 35 cases (55.6%). The mean VHI‐10 score improved from 27.2 ± 8.1 to 11.4 ± 7.9 in the NFR group and from 26.3 ± 4.9 to 9.7 ± 7.9 in the FR group. The success rates were 66.6% in the NFR group and 71.5% in the FR group. No statistical difference was observed in the improvement in the mean VHI‐10 scores, and the success rate between the two groups. However, two cases resulted in failure in the FR group, whereas no worsened case was observed in the NFR group.ConclusionThe current TI used in T2T has low durability and could result in the worsening of vocal symptoms after the surgery.Level of Evidence4 Laryngoscope, 2023

show abstract

Treatment Outcome Measures for Spasmodic Dysphonia: A Systematic Review

Cited by 6 publications

References 152 publications

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

Exploring Patient's Preference of Patient‐Reported Outcome Measures in Laryngeal Movement Disorders

Durability of Titanium Implants Following Type II Thyroplasty for Adductor Type Spasmodic Dysphonia

Contact Info

Product

Resources

About